Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia

M. Rihacek, J. Bienertova-Vasku, D. Valik, J. Sterba, K. Pilatova, L. Zdrazilova-Dubska,

. 2015 ; 2015 (-) : 792187. [pub] 20150803

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc16020324

B-cell activating factor (BAFF) is a cytokine and adipokine of the TNF ligand superfamily. The main biological function of BAFF in maintaining the maturation of B-cells to plasma cells has recently made it a target of the first FDA-approved selective BAFF antibody, belimumab, for the therapy of systemic lupus erythematosus. Concomitantly, the role of BAFF in cancer has been a subject of research since its discovery. Here we review BAFF as a biomarker of malignant disease activity and prognostic factor in B-cell derived malignancies such as multiple myeloma. Moreover, anti-BAFF therapy seems to be a promising approach in treatment of B-cell derived leukemias/lymphomas. In nonhematologic solid tumors, BAFF may contribute to cancer progression by mechanisms both dependent on and independent of BAFF's proinflammatory role. We also describe ongoing research into the pathophysiological link between BAFF and cancer-related cachexia. BAFF has been shown to contribute to inflammation and insulin resistance which are known to worsen cancer cachexia syndrome. Taking all the above together, BAFF is emerging as a biomarker of several malignancies and a possible hallmark of cancer cachexia.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020324
003      
CZ-PrNML
005      
20160725124606.0
007      
ta
008      
160722s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2015/792187 $2 doi
024    7_
$a 10.1155/2015/792187 $2 doi
035    __
$a (PubMed)26339644
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rihacek, Michal $u Department of Pediatric Oncology, University Hospital and Faculty of Medicine, Masaryk University, Cernopolni 9, 613 00 Brno, Czech Republic ; Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic.
245    10
$a B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia / $c M. Rihacek, J. Bienertova-Vasku, D. Valik, J. Sterba, K. Pilatova, L. Zdrazilova-Dubska,
520    9_
$a B-cell activating factor (BAFF) is a cytokine and adipokine of the TNF ligand superfamily. The main biological function of BAFF in maintaining the maturation of B-cells to plasma cells has recently made it a target of the first FDA-approved selective BAFF antibody, belimumab, for the therapy of systemic lupus erythematosus. Concomitantly, the role of BAFF in cancer has been a subject of research since its discovery. Here we review BAFF as a biomarker of malignant disease activity and prognostic factor in B-cell derived malignancies such as multiple myeloma. Moreover, anti-BAFF therapy seems to be a promising approach in treatment of B-cell derived leukemias/lymphomas. In nonhematologic solid tumors, BAFF may contribute to cancer progression by mechanisms both dependent on and independent of BAFF's proinflammatory role. We also describe ongoing research into the pathophysiological link between BAFF and cancer-related cachexia. BAFF has been shown to contribute to inflammation and insulin resistance which are known to worsen cancer cachexia syndrome. Taking all the above together, BAFF is emerging as a biomarker of several malignancies and a possible hallmark of cancer cachexia.
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    _2
$a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
650    _2
$a faktor aktivující B-buňky $x genetika $7 D053264
650    _2
$a B-lymfocyty $x metabolismus $x patologie $7 D001402
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a kachexie $x genetika $x patologie $7 D002100
650    _2
$a lidé $7 D006801
650    _2
$a systémový lupus erythematodes $x farmakoterapie $x genetika $7 D008180
650    _2
$a mnohočetný myelom $x genetika $x patologie $7 D009101
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Bienertova-Vasku, Julie $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic ; Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
700    1_
$a Valik, Dalibor $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic ; Advanced Cell Immunotherapy Unit, Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
700    1_
$a Sterba, Jaroslav $u Department of Pediatric Oncology, University Hospital and Faculty of Medicine, Masaryk University, Cernopolni 9, 613 00 Brno, Czech Republic ; Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic.
700    1_
$a Pilatova, Katerina $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic ; Advanced Cell Immunotherapy Unit, Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
700    1_
$a Zdrazilova-Dubska, Lenka $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic ; Advanced Cell Immunotherapy Unit, Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
773    0_
$w MED00182164 $t BioMed research international $x 2314-6141 $g Roč. 2015, č. - (2015), s. 792187
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26339644 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160725124825 $b ABA008
999    __
$a ok $b bmc $g 1154994 $s 944852
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 2015 $c - $d 792187 $e 20150803 $i 2314-6141 $m BioMed research international $n Biomed Res Int $x MED00182164
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Možnosti archivace